CORDIS
EU research results

CORDIS

English EN

Scaling-up biodegradable nanomedicines for multimodal for multimodal precision cancer immunotherapy

Project information

Grant agreement ID: 686089

Status

Ongoing project

  • Start date

    1 May 2016

  • End date

    30 April 2021

Funded under:

H2020-EU.2.1.2.

  • Overall budget:

    € 8 291 217,50

  • EU contribution

    € 8 291 217,50

Coordinated by:

STICHTING KATHOLIEKE UNIVERSITEIT

Netherlands

Objective

PRECIOUS aims at scaling-up biodegradable nanomedicines for multimodal precision cancer immunotherapy.
With 3.5 million cancer patients in Europe every year, new cancer medicines are eagerly awaited, notably for prostate and ovarian cancer.
Systemically applied new immunotherapies are promising, but their toxicity is a hurdle. Vaccination against cancer is safe but rather the efficacy can be disappointing, i.e. the microenvironment shuts down anti-tumour immunity.

PRECIOUS will tackle 2 bottlenecks:
1. Production of non toxic multimodal nanomedicines, which induce vigorous immune responses, and at the same time reverse immunosuppression
2. Large scale GMP production of nanomedicines, and initiate a multimodal immunotherapy Phase I trial.

We want to solve these bottlenecks by:
Objective 1: Two types of GMP biodegradable nanoparticles: 1) a nanovaccine, containing tumour antigens and immune activators, and 2) a nanoparticle composed of compounds, which reverses the suppression and reactivates immunity in the tumour.
Objective 2: Clinical Phase I trial to show efficacy. Nanomedicines will be used by 1) injection of vaccines to evoke immune responses and 2) injection of nanoparticles in the tumour microenvironment, which slowly release compounds that reverse suppression.

To achieve this, a platform is formed with 6 leading industrial partners to produce large scale GMP nanomedicines and an excellent immunomodulator track record, together with 5 renowned academic partners to perform clinical studies.
Relevance to call: Large scale GMP production, industrial leadership, nanotechnology and advanced manufacturing KET technologies, translation to the clinic, marketing development.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

STICHTING KATHOLIEKE UNIVERSITEIT

Address

Geert Grooteplein Noord 9
6525 Ez Nijmegen

Netherlands

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 802 005,94

Participants (10)

EVONIK NUTRITION & CARE GMBH

Germany

EU Contribution

€ 838 549,53

ITEOS THERAPEUTICS

Belgium

EU Contribution

€ 952 222,61

IOX THERAPEUTICS LIMITED

United Kingdom

EU Contribution

€ 242 295,84

ONCOARENDI THERAPEUTICS SPOLKA AKCYJNA

Poland

EU Contribution

€ 617 854,38

SPECIALIZED MEDICAL SERVICES-ONCOLOGY BV

Netherlands

EU Contribution

€ 722 689,73

UNIVERSITAT KONSTANZ

Germany

EU Contribution

€ 828 126,10

USTAV MAKROMOLEKULARNI CHEMIE AV CRVVI

Czechia

EU Contribution

€ 464 238,81

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom

EU Contribution

€ 984 650,70

FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI

Italy

EU Contribution

€ 693 206,36

TTOPSTART BV

Netherlands

EU Contribution

€ 145 377,50

Project information

Grant agreement ID: 686089

Status

Ongoing project

  • Start date

    1 May 2016

  • End date

    30 April 2021

Funded under:

H2020-EU.2.1.2.

  • Overall budget:

    € 8 291 217,50

  • EU contribution

    € 8 291 217,50

Coordinated by:

STICHTING KATHOLIEKE UNIVERSITEIT

Netherlands